Masahiro Niwa

Purification and biological property of heparin cofactor II: Activation of heparin cofactor II and antithrombin III by dextran sulfate and various glycosaminoglycans

Heparin cofactor II (HC II) has been purified from human plasma by a modification of the method described by Tollefsen et al. (J. Biol. Chem., 257, 2162, 1982) and abilities of dextran sulfate and various glycosaminoglycans to activate the antithrombin activities of HC II and antithrombin III (AT III) were studied. By the purification method described here, highly purified HC II with the same specific activity as reported by Tollefsen et al. was obtained with a higher yield and in a shorter purification time. Heparin, dextran sulfate and chondroitin polysulfates 1 and 5 activated both HC II and AT III, while dermatan sulfate activated only HC II. Dextran sulfate was almost as active as heparin in the activation of HC II and AT III, indicating that in the interactions of heparin with HC II and AT III, sulfate groups of heparin are more important than carboxyl groups. When mixed with thrombin in the presence of dermatan sulfate, normal human plasma showed antithrombin activity which was not due to AT III but to HC II only. HC II did not inhibit factor Xa or plasmin in the presence of any glycosaminoglycans or dextran sulfate, suggesting that HC II would be a specific inhibitor of thrombin.

Studies on the effect of PEG-modified urokinase on coagulation-fibrinolysis using beagles

Urokinase (UK), a human urinary plasminogen activator, was modified by the covalent attachment of methoxypolyethylene glycol (PEG) of 5,000 daltons. There were observed changes in substrate specificity and an increase in molecular weight in PEG-modified UK (PEG-UK). We evaluated PEG-UK by ex vivo study using beagles, and found that UK activity in the blood was well maintained over hours after intravenous injection, and that fibrinolysis was more activated compared with native UK by coagulation-fibrinolysis studies.

Thrombin inhibitory activity of heparin cofactor ii depends on the molecular weight and sulfate amount of dextran sulfate

The effect of molecular weight and sulfate amount of sulfated polysaccharide on the thrombin inhibitory activity of heparin cofactor II was investigated by using various dextran sulfate fractions with different molecular weight and sulfur content. The activity of dextran sulfate fractions of each size increased as the sulfur content was increased from 9 to 18%, and the activity decreased in molecules below 10 kDa. The maximum second order rate constant of heparin cofactor II-thrombin reaction in the presence of the fractions of over-10 kDa and 18% sulfur was 2.7 X 10(8) M-1 min-1 that was almost same as in the presence of heparin or dermatan sulfate. On the other hand, dextran sulfate accelerated antithrombin III-thrombin reaction only about 40-fold less than heparin. These results indicate that a large molecular size and significant amount of sulfate groups are only essential in the acceleration of the thrombin inhibitory activity of heparin cofactor II, whereas a specific sequence of heparin is required to that of antithrombin III.

Specificity of sulfated polysaccharides to accelerate the inhibition of activated protein C by protein C inhibitor

The ability of various sulfated polysaccharides to activate protein C inhibitor (PCI) and the effect of molecular weight (Mr) and sulfur content of dextran sulfates were investigated. Besides dextran sulfate, highly sulfated polysaccharides such as chondroitin polysulfates 1 and 5, and pentosan polysulfate were more active than heparin in enhancing the activated protein C inhibition by PCI. The molecular weight and the sulfur content of dextran sulfate were critical for the second-order rate constant of the reaction and for the optimal concentration of the polysaccharide, respectively. These results suggest that the carboxyl groups of polysaccharides are not necessarily required, but some sulfate groups within polymers may play a critical role in the interaction with PCI.

Studies on Wakan-Yakus (traditional herbal drugs) : Especially on the effects of Gaiyoh (Artemisiae folium) on blood coagulation

Wakan-Yakus (traditional herbal drugs) such as Akyoh (Glutinum), Gaiyoh (Artemisiae folium), Sanshishi (Gardeniae fructus), Kizutsu (Aurantii fructus), and Taisoh (Zizyphi fructus) were studied in relation to their effects on blood coagulation-fibrinolysis. (1) All of the water extracts of the Wakan-Yakus prolonged aPTT and PT. The potency of the effectiveness on aPTT was in the order of Gaiyoh (Artemisiae folium) greater than Kizutsu (Aurantii fructus) greater than Sanshishi (Gardeniae fructus) greater than Taisoh (Zizyphi fructus) greater than Akyoh (Glutinum). (2) Gaiyoh (Artemisiae folium) greater than Kizutsu (Aurantii fructus) greater than Akyoh (Glutinum) greater than Taisoh (Zizyphi fructus) showed the antifibrinolytic effects in this order. On the other hand, Sanshishi showed the accelerating effect on fibrinolysis. (3) The inhibition modes of both thrombin and plasmin by Gaiyoh (Artemisiae folium) were shown to be competitive on Lineweaver-Burk plot. (4) Gaiyoh (Artemisiae folium) was gel-filtered on Sephadex G-25 column (1.5 X 90cm) equilibrated with distilled water at room temperature. Five fractions were obtained, and in the first to fourth fraction, strong anticoagulant effects on aPTT and PT were observed. We pooled first and second to make fraction I, and make fraction II from peak 3. The recovery rate was 4.2% by weight, and 36.7% by inhibition activity, and specific activity on the basis of inhibition to aPTT was 34.8% U/mg in the case with fraction II. Fraction I was found to be the same characteristically on blood coagulation. Fraction II was further purified by Sephadex LH-20 column (1.5 X 80 cm) at room temperature. Three fractions (Fraction IIa, IIb, IIc) were obtained, and the strong inhibitory effects was observed on both aPTT and PT in each fraction. The first fraction (fraction IIa) showed the strong inhibitory effect on aPTT, and the heightened specific activity with 17.6% as the recovery rate.